<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04085809</url>
  </required_header>
  <id_info>
    <org_study_id>0123-02-01</org_study_id>
    <nct_id>NCT04085809</nct_id>
  </id_info>
  <brief_title>This Was a Clinical Study Investigating the Moisturization and Desquamation Effect of AmLactin® Rapid Relief Restoring Lotion + Ceramides on Dry Skin in Healthy Female Volunteers. AmLactin® Rapid Relief is an Over-the-counter Cosmetic</brief_title>
  <official_title>A 14-Day, Single-Blind, Controlled Study to Assess the Qualitative Improvement in Skin Moisturization and Desquamation of AmLactin® Rapid Relief Treatment in Healthy Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to investigate if AmLactin® Rapid Relief improves the
      skin through desquamation and moisturization via D-SQUAME analysis. AmLactin® Rapid Relief is
      an over-the-counter cosmetic.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Actual">April 8, 2019</completion_date>
  <primary_completion_date type="Actual">April 8, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Upon enrollment, each subject received a randomization code, indicating which leg the study product had to be applied (the other leg received no study product). Each subject in this study served as her own control.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in D-SQUAME</measure>
    <time_frame>Baseline, Day 2, Day 14</time_frame>
    <description>D-SQUAME is a sticky tape that is placed on the skin and the more skin that comes off on the tape, the drier the skin and less moisturization and desquamation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in overall dry skin scale</measure>
    <time_frame>Baseline, Day 2, Day 14</time_frame>
    <description>An evaluation of the skin by a blinded Investigator was utilized to assess the overall appearance of the skin on an ordinal scale from 0 = none to 4 = severe in five domains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Skin Dryness assessed by Dry Skin Scale</measure>
    <time_frame>Baseline, Day 2, Day 14</time_frame>
    <description>An evaluation of the skin by a blinded Investigator was utilized to assess the overall appearance of the skin on an ordinal scale from 0 = none to 4 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Skin Texture/Roughness (Tactile) assessed by Dry Skin Scale assessed by Dry Skin Scale</measure>
    <time_frame>Baseline, Day 2, Day 14</time_frame>
    <description>An evaluation of the skin by a blinded Investigator was utilized to assess the overall appearance of the skin on an ordinal scale from 0 = none to 4 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Skin Texture/Roughness (Visual) assessed by Dry Skin Scale</measure>
    <time_frame>Baseline, Day 2, Day 14</time_frame>
    <description>An evaluation of the skin by a blinded Investigator was utilized to assess the overall appearance of the skin on an ordinal scale from 0 = none to 4 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Desquamation/Flakiness assessed by Dry Skin Scale</measure>
    <time_frame>Baseline, Day 2, Day 14</time_frame>
    <description>An evaluation of the skin by a blinded Investigator was utilized to assess the overall appearance of the skin on an ordinal scale from 0 = none to 4 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Luminosity/Radiance assessed by Dry Skin Scale</measure>
    <time_frame>Baseline, Day 2, Day 14</time_frame>
    <description>An evaluation of the skin by a blinded Investigator was utilized to assess the overall appearance of the skin on an ordinal scale from 0 = none to 4 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Subject Self-Assessment Questionnaire</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <description>Subjects rated the skin attributes of the treated leg in nine domains on a scale from 0 - 4 .</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Dry Skin</condition>
  <arm_group>
    <arm_group_label>Left Leg: AmLactin® Rapid Relief / Right Leg: No Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AmLactin® Rapid Relief, BID application for 14 days on left leg and no treatment on right leg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Left Leg: No Treatment / Right Leg: AmLactin® Rapid Relief</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AmLactin® Rapid Relief, BID application for 14 days on right leg and no treatment on left leg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AmLactin® Rapid Relief</intervention_name>
    <description>AmLactin® Rapid Relief, BID application for 14 days. AmLactin is an over-the-counter cosmetic.</description>
    <arm_group_label>Left Leg: AmLactin® Rapid Relief / Right Leg: No Treatment</arm_group_label>
    <arm_group_label>Left Leg: No Treatment / Right Leg: AmLactin® Rapid Relief</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy female (confirmed by medical history) with Fitzpatrick skin types I-VI

          -  dry, rough skin on the anterior shins (defined as Grade 3-4 on the dermatologist
             evaluation of the skin);

        Exclusion Criteria:

        - Had any visible skin disease at the assessment site which, in the opinion of the
        Investigator, would interfere with the evaluation of the test site
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only female participants were being studied</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sandoz Investigational Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>September 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

